Cetuximab and Methotrexate in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma‐ A Single Institution Analysis of 54 Patients

Abstract

Cetuximab (CTX) and methotrexate (MTX) have both shown single‐agent activity in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) but data on CTX/MTX combination is limited.

We report safety and efficacy data of 54 R/M HNSCC patients treated with concurrent CTX/MTX.

Median progression‐free survival and overall survival were 2.98 months (95% CI, 2.16‐4.85 months) and 8.66 months (95% CI, 7.02‐12.26 months), respectively.

Grade 3 rash and hypomagnesemia were observed in four (7%) and two (4%) of patients.

CTX/MTX combination could be considered as a palliative treatment option for patients with R/M HNSCC.

This article is protected by copyright. All rights reserved.

https://ift.tt/2SPOnjk